These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Roles of G beta gamma in membrane recruitment and activation of p110 gamma/p101 phosphoinositide 3-kinase gamma. Brock C; Schaefer M; Reusch HP; Czupalla C; Michalke M; Spicher K; Schultz G; Nürnberg B J Cell Biol; 2003 Jan; 160(1):89-99. PubMed ID: 12507995 [TBL] [Abstract][Full Text] [Related]
26. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Miled N; Yan Y; Hon WC; Perisic O; Zvelebil M; Inbar Y; Schneidman-Duhovny D; Wolfson HJ; Backer JM; Williams RL Science; 2007 Jul; 317(5835):239-42. PubMed ID: 17626883 [TBL] [Abstract][Full Text] [Related]
27. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113 [TBL] [Abstract][Full Text] [Related]
28. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Zhao L; Vogt PK Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2652-7. PubMed ID: 18268322 [TBL] [Abstract][Full Text] [Related]
29. Positive and negative regulation of phosphoinositide 3-kinase-dependent signaling pathways by three different gene products of the p85alpha regulatory subunit. Ueki K; Algenstaedt P; Mauvais-Jarvis F; Kahn CR Mol Cell Biol; 2000 Nov; 20(21):8035-46. PubMed ID: 11027274 [TBL] [Abstract][Full Text] [Related]
30. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Luo J; Cantley LC Cell Cycle; 2005 Oct; 4(10):1309-12. PubMed ID: 16131837 [TBL] [Abstract][Full Text] [Related]
31. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Kang S; Denley A; Vanhaesebroeck B; Vogt PK Proc Natl Acad Sci U S A; 2006 Jan; 103(5):1289-94. PubMed ID: 16432180 [TBL] [Abstract][Full Text] [Related]
32. The p85 and p110 subunits of phosphatidylinositol 3-kinase-alpha are substrates, in vitro, for a constitutively associated protein tyrosine kinase in platelets. Geltz NR; Augustine JA Blood; 1998 Feb; 91(3):930-9. PubMed ID: 9446654 [TBL] [Abstract][Full Text] [Related]
33. The PI 3-kinase isoforms p110(alpha) and p110(beta) have differential roles in PDGF- and insulin-mediated signaling. Hooshmand-Rad R; Hájková L; Klint P; Karlsson R; Vanhaesebroeck B; Claesson-Welsh L; Heldin CH J Cell Sci; 2000 Jan; 113 Pt 2():207-14. PubMed ID: 10633072 [TBL] [Abstract][Full Text] [Related]
34. A synthetic peptide hijacks the catalytic subunit of class I PI3K to suppress the growth of cancer cells. Guo W; You X; Wang X; Wang L; Chen Y Cancer Lett; 2017 Oct; 405():1-9. PubMed ID: 28743532 [TBL] [Abstract][Full Text] [Related]
35. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis. Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298 [TBL] [Abstract][Full Text] [Related]
36. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease. Rathinaswamy MK; Burke JE Adv Biol Regul; 2020 Jan; 75():100657. PubMed ID: 31611073 [TBL] [Abstract][Full Text] [Related]
37. Activity of the p110-alpha subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport. Wang J; Knight ZA; Fiedler D; Williams O; Shokat KM; Pearce D Am J Physiol Renal Physiol; 2008 Sep; 295(3):F843-50. PubMed ID: 18653476 [TBL] [Abstract][Full Text] [Related]
38. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Engelman JA; Chen L; Tan X; Crosby K; Guimaraes AR; Upadhyay R; Maira M; McNamara K; Perera SA; Song Y; Chirieac LR; Kaur R; Lightbown A; Simendinger J; Li T; Padera RF; García-Echeverría C; Weissleder R; Mahmood U; Cantley LC; Wong KK Nat Med; 2008 Dec; 14(12):1351-6. PubMed ID: 19029981 [TBL] [Abstract][Full Text] [Related]
39. Phosphoinositide 3-kinase: from viral oncoprotein to drug target. Vogt PK; Bader AG; Kang S Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744 [TBL] [Abstract][Full Text] [Related]
40. The structure of the inter-SH2 domain of class IA phosphoinositide 3-kinase determined by site-directed spin labeling EPR and homology modeling. Fu Z; Aronoff-Spencer E; Backer JM; Gerfen GJ Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3275-80. PubMed ID: 12629217 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]